Prognostic value of ischemic modified albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
10.3760/cma.j.issn.1671-7368.2013.06.024
- VernacularTitle:缺血修饰白蛋白与介入治疗非ST段抬高急性冠状动脉综合征预后的关系
- Author:
Ya LIU
;
Shan YAN
;
Shaojun WEN
;
Jielin LIU
;
Zuoguang WANG
;
Xuefeng ZHANG
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Ischemic modified albumin
- From:
Chinese Journal of General Practitioners
2013;(6):472-474
- CountryChina
- Language:Chinese
-
Abstract:
Two hundred and fourteen patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) underwent percutaneous coronary intervention (PCI).Serum ischemic modified albumin (IMA) levels were measured in patients at admission.The major adverse cardiac events (MACE),including cardiac death,nonfatal myocardial infarction (MI) and recurrent ischemia leading to urgent revascularization were observed during 1-y period of follow-up.Receiver operating characteristic (ROC) curves,Kaplan-Meier analysis and Cox regression were used to assess the prognostic value of IMA for 1-y MACE.Twenty one patients experienced major adverse cardiac events during 1-y follow up period,including 6 cases of cardiac death,8 cases of new or recurrent MI,7 cases of target vessel/lesion revascularization or coronary artery bypass grafting (CABG).ROC showed that the area under the ROC curve (AUC) was 0.667,and when IMA was used to predict 1-y major adverse cardiac events,the cut-off value of 65.3 kU/L was most effective.Kaplan-Meier analysis showed that IMA was significantly correlated with the occurrence of 1-y MACE(P ＜ 0.01).But Cox regression model showed that IMA levels were not independent risk factor for 1-y MACE in NSTEACS patients,when adjusted with other risk factors.
